Clinical Trial Update: Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization [Phase 2]

View source ↗

Summary

Phase II study evaluating sunitinib malate after hepatic artery embolization in neuroendocrine and islet cell tumors; the trial is completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Islet Cell Tumor
• Neuroendocrine Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Neuroendocrine Tumor, Islet Cell Tumor | Phase 2 | Status: COMPLETED | Results posted: 2012-09-07